Form 144 Kymera Therapeutics, Filed by: Mainolfi Nello
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Citi Opens 90-Day Upside Catalyst Watch on Kymera Therapeutics (KYMR)
October 5, 2026 5:24 AM EDTCiti analyst Geoff Meacham reiterated a Buy rating and $150.00 price target on Kymera Therapeutics (NASDAQ: KYMR)
Opens 90-Day Upside Catalyst Watch.For an analyst ratings summary and ratings history on Kymera Therapeutics click here. For more ratings news on Kymera Therapeutics click here.
Shares of Kymera Therapeutics closed at $107.39 yesterday.
... More


